We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Portable RT-PCR Molecular Test Detects Dengue Virus with High Accuracy

By LabMedica International staff writers
Posted on 06 May 2022
Print article
Image: Portable RT-PCR molecular instrument tests for dengue virus (Photo courtesy of Anitoa Systems)
Image: Portable RT-PCR molecular instrument tests for dengue virus (Photo courtesy of Anitoa Systems)

Dengue virus infections can potentially lead to severe outcomes or death in patients. There is currently no approved vaccines and medicine for dengue infection, although researchers have shown that early detection and intervention can bring about much more favorable outcome in patients and relief the burdens of families and health care facilities affected. Nucleic acid tests such as multiplex RT-PCR tests are more accurate and predictive than alternative anti-body-based tests. Now, a new dengue RT-PCR virus test detects the presence of dengue virus infections with a high level of accuracy.

Anitoa Systems, LLC (Sunnyvale, CA, USA) has launched a turn-key RT-PCR solution for testing dengue virus that includes one of a family of 4-6 channel small foot-print RT PCR instruments called the Maverick qPCR, with a one-step multiplex RT-PCR reagent offered in lyophilized format. Lyophilized reagents are easy to transport, without the need for refrigeration. The multiplex test detects several target genes in a sample, which are shown by researchers to be highly expressed in patients that later develops serious symptoms.

Anitoa's Maverick line of real time PCR devices are lab-accurate multi-plex qPCR instruments in a small format. They can operate on battery power (including car battery) and takes up very little bench space. Maverick qPCR instruments are built on Anitoa's proprietary CMOS image sensor-based fluorescence and chemiluminescence molecular imaging technology. By replacing the traditional bulky and costly photon-multiplier tube (PMT) and CCD-based optical sub-systems, Anitoa's ultra-low-light CMOS sensor technology enables a new generation of compact and inexpensive molecular testing platforms targeting infectious, oncology and cardio-vascular markers. Anitoa's dengue virus detection solution is part of an on-going program at the company to develop tests to help combat a series of neglected tropical diseases in low resource settings.

"We are excited to be part of the community that offer advanced diagnostic solutions for a series of neglected tropical infections. We would like to use our technology and expertise to improve our ability to address this unmet market need," said Zhimin ding, CEO of Anitoa Systems, LLC.

Related Links:
Anitoa Systems, LLC 

Gold Supplier
COVID-19 Immune Response Test
Quan-T-Cell
New
Automatic Hematology Analyzer
BF-7200Plus
New
Urine Analyzer
R-600S
New
3-DIFF Hematology Analyzer
MYTHIC 18

Print article

Channels

Clinical Chem.

view channel
Image: The analysis pipeline used to investigate associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer’s disease (Photo courtesy of University College London)

Lipid Measurements Show Potential as Alzheimer’s Disease Biomarkers

Brain changes accompanying ageing are varied and can include pathologies that lead to cognitive impairment, the commonest of which is Alzheimer’s disease (AD). Identifying blood-based signatures of brain... Read more

Hematology

view channel
Image: Standard test for multiple myeloma provides clues of a rare, more deadly type (Photo courtesy of Pexels)

Standard Blood Cancer Test Provides Clues of Rare IgD Multiple Myeloma

IgD myeloma accounts for about 1% of common blood cancer multiple myeloma and has a worse prognosis. Specific testing for IgD myeloma is available at a handful of reference labs across the US, but takes... Read more

Industry

view channel
Image: QIAGEN has acquired a majority stake in enzymes provider BLIRT S.A. (Photo courtesy of QIAGEN)

Qiagen Acquires Enzymes Provider Blirt to Strengthen Sample Technologies Business

QIAGEN N.V. (Venlo, Netherlands) has signed agreements to acquire a 96% majority ownership stake in BLIRT S.A. (Gdansk, Poland), a manufacturer of recombinant enzymes for the life science industry.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.